Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

60.35
-0.3900-0.64%
Pre-market: 60.400.0500+0.08%08:36 EST
Volume:12.87M
Turnover:775.45M
Market Cap:122.86B
PE:17.44
High:61.30
Open:60.85
Low:59.48
Close:60.74
52wk High:63.33
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:1.02
T/O Rate:0.63%
Dividend:2.49
Dividend Rate:4.13%
EPS(TTM):3.46
EPS(LYR):3.46
ROE:40.44%
ROA:10.29%
PB:6.65
PE(LYR):17.44

Loading ...

Company Profile

Company Name:
Bristol-Myers Squibb
Exchange:
NYSE
Establishment Date:
1887
Employees:
32500
Office Location:
Route 206 & Province Line Road,Princeton,New Jersey,United States
Zip Code:
08543
Fax:
- -
Introduction:
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Directors

Name
Position
Christopher Boerner
Chair of the Board and Chief Executive Officer
Deepak L. Bhatt
Independent Director
Derica W. Rice
Independent Director
Julia A. Haller
Independent Director
Karen H. Vousden
Independent Director
Manuel Hidalgo Medina
Independent Director
Paula A. Price
Independent Director
Peter J. Arduini
Independent Director
Phyllis R. Yale
Independent Director
Theodore R. Samuels
Independent Director
Michael R. McMullen
Director

Shareholders

Name
Position
Christopher Boerner
Chair of the Board and Chief Executive Officer
David V. Elkins
Chief Financial Officer and Executive Vice President
Phil Holzer
Controller and Senior Vice President
Adam Lenkowsky
Chief Commercialization Officer
Benjamin Hickey
President, RayzeBio Organization
Cari Gallman
Chief Policy Officer and Executive Vice President and General Counsel
Cristian Massacesi
Chief Medical Officer and Executive Vice President and Head of Development
Greg Meyers
Chief Digital and Technology Officer
Hiroshi Chris Shibutani
Chief Strategy Officer and Executive Vice President
Karin Shanahan
Chief Supply Chain & Operations and Executive Vice President
Lynelle Hoch
President, Cell Therapy Organization
Robert Plenge
Executive Vice President, Chief Research Officer, Head of Research
Wendy Short Bartie
Executive Vice President, Corporate Affairs